Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
As of close of business last night, C4 Therapeutics Inc’s stock clocked out at $4.25, up 5.99% from its previous closing price of $4.01. In other words, the price has increased by $5.99 from its previous closing price. On the day, 1.36 million shares were traded. CCCC stock price reached its highest trading level at $4.3385 during the session, while it also had its lowest trading level at $3.92.
Ratios:
To gain a deeper understanding of CCCC’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.31 and its Current Ratio is at 6.31. In the meantime, Its Debt-to-Equity ratio is 0.28 whereas as Long-Term Debt/Eq ratio is at 0.25.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Stephens on November 18, 2024, initiated with a Equal-Weight rating and assigned the stock a target price of $4.
On January 29, 2024, JP Morgan Upgraded its rating to Neutral which previously was Underweight but kept the price unchanged to $6.
Stifel Upgraded its Hold to Buy on December 13, 2023, whereas the target price for the stock was revised from $2 to $12.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 18 ’24 when Salter Malcolm bought 13,000 shares for $4.19 per share.
Salter Malcolm bought 13,000 shares of CCCC for $83,321 on Oct 18 ’24. On Oct 11 ’24, another insider, Salter Malcolm, who serves as the Director of the company, bought 8,561 shares for $5.38 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CCCC now has a Market Capitalization of 300003264 and an Enterprise Value of 111457072. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.44 while its Price-to-Book (P/B) ratio in mrq is 1.24. Its current Enterprise Value per Revenue stands at 3.31 whereas that against EBITDA is -0.968.
Stock Price History:
Over the past 52 weeks, CCCC has reached a high of $11.88, while it has fallen to a 52-week low of $1.06. The 50-Day Moving Average of the stock is -25.16%, while the 200-Day Moving Average is calculated to be -33.75%.
Shares Statistics:
It appears that CCCC traded 1.01M shares on average per day over the past three months and 1168430 shares per day over the past ten days. A total of 60.47M shares are outstanding, with a floating share count of 56.67M. Insiders hold about 19.72% of the company’s shares, while institutions hold 83.25% stake in the company. Shares short for CCCC as of 1730332800 were 5854503 with a Short Ratio of 5.79, compared to 1727654400 on 11011767. Therefore, it implies a Short% of Shares Outstanding of 5854503 and a Short% of Float of 10.05.
